AR056688A1 - DERIVATIVES OF THE 4- AMINO - QUINAZOLINA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS - Google Patents

DERIVATIVES OF THE 4- AMINO - QUINAZOLINA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS

Info

Publication number
AR056688A1
AR056688A1 ARP060104457A ARP060104457A AR056688A1 AR 056688 A1 AR056688 A1 AR 056688A1 AR P060104457 A ARP060104457 A AR P060104457A AR P060104457 A ARP060104457 A AR P060104457A AR 056688 A1 AR056688 A1 AR 056688A1
Authority
AR
Argentina
Prior art keywords
alkylene
group
alkyl
aryl
nrarb
Prior art date
Application number
ARP060104457A
Other languages
Spanish (es)
Inventor
Jean Michel Augereau
Gilles Courtemanche
Pierre Despeyroux
Michel Geslin
Anne Thomas
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645639&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056688(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR056688A1 publication Critical patent/AR056688A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

utiles para trastornos metabolicos. Reivindicacion 1: Compuesto que responde a la formula general (1) en la que: A representa un grupo alquileno C1-4 opcionalmente sustituido con uno o varios grupos R9 idénticos o diferentes uno de otro; B representa un grupo alquileno C1-4 opcionalmente sustituido con uno o varios grupos R10 idénticos o diferentes uno de otro; R9 y R10 representan cada uno, de manera independiente el uno del otro, un átomo de H o un grupo alquilo C1-5; o bien R9 y R10 forman juntos un enlace sencillo o un grupo alquileno C1-4; L representa un enlace sencillo o un grupo alquileno C1-2, -CH=CH- o -C:::C-, estando los grupos alquileno C1-2 y-CH=CH- opcionalmente sustituidos con uno o varios sustituyentes alquilo C1-2 o bien L representa un grupo cicloprop-1,2-di-ilo; R representa un átomo de H o un grupo alquilo C1-5, fluoroalquilo C1-3, cicloalquilo C3-6, -C(O)-alquilo C1-3, alquileno C1-3-cicloalquilo C3-6, -CH2-C:::CH, alquileno C2-4-NRaRb o alquileno C1- 3-X-alquilo C1-3 en el que X representa O o SO2; R1 representa un arilo o un heteroarilo; estando los grupos arilo y heteroarilo opcionalmente sustituidos con uno o varios radicales Z idénticos o diferentes uno de otro, R2 y R3 representan, de forma independiente el uno del otro, un átomo de H o un grupo alquilo C1-3 o fluoroalquilo C1-3; o bien R2 y R3 forman juntos, con el átomo de C que los soporta, un grupo cicloprop-1,1-di-ilo; R4 representa: un átomo de H o un grupo alquilo C1-5, fluoroalquilo C1-3, alcoxi C1-5, -SF5 o alquileno C1-3-X-alquilo C1-3 en el que X representa O o SO2, un grupo alquileno C1-5-NRaRb, un arilo o un heteroarilo; estando los grupos arilo y heteroarilo opcionalmente sustituidos con uno o varios radicales Z idénticos o diferentes uno de otro; R5 representa un átomo de H o de halogeno o un grupo alquilo C1-5, fluoroalquilo C1-3, alcoxi C1-5, cicloalquilo C3-6, alquileno C1-3-cicloalquilo C3-6, alquileno C1-3-O-alquilo C1-3, alquileno C1-3- (OH) o alquileno C1-3-X-alquilo C1-3 en el que X representa S, SO o SO2, o bien R5 representa un grupo -NRaRb, alquileno C1-3-NRaRb, arilo, alquileno C1-3-arilo, -O-arilo, alquileno C1-3-O-arilo, alquileno C1-3-O-alquileno C1-3-arilo, heteroarilo o alquileno C1-3-heteroarilo; estando los grupos arilo, alquileno C1-3-arilo, -O-arilo, alquileno C1-3-O-arilo, alquileno C1-3-O-alquileno C1-3-arilo, heteroarilo y alquileno C1-3-heteroarilo opcionalmente sustituidos con uno o varios radicales Z idénticos o diferentes uno de otro, o bien R5 representa un grupo heterociclo, estando dicho heterociclo opcionalmente sustituido con un grupo alquilo C1-3, -C(O)-alquilo C1-3, -C(O)-fluoroalquilo C1-3, alquileno C1-3-cicloalquilo C3-6, alquileno C1- 3-arilo o alquileno C1-3-heteroarilo; estando los grupos alquileno C1-3-arilo y alquileno C1-3-heteroarilo opcionalmente sustituidos con uno o varios radicales Z idénticos diferentes uno de otro; R7 representa un átomo de H o de halogeno o un grupo alquilo C1-5, fluoroalquilo C1-3, alcoxi C1-5, -COOH, -C(O)O-alquilo C1-3, fluoroalcoxi C1-3, alquileno C1-3-(OH), -NO2, -CN o -X-alquilo C1-3 en el que X representa S, SO o SO2, o bien R7 representa un grupo -NRaRb, alquileno C1-3-NRaRb, -C(O)- NRaRb, -C(O)-alquilo C1-3, arilo, -O-arilo o heteroarilo; estando los grupos arilo, -O-arilo y heteroarilo opcionalmente sustituidos con uno o varios radicales Z idénticos o diferentes uno de otro; Z representa un átomo de halogeno o un grupo alquilo C1-5, fluoroalquilo C1-3, cicloalquilo C3-6, alquileno C1-3-cicloalquilo C3-6, un fenilo, alcoxi C1-5, fluoroalcoxi C1-3, alquileno C1-3-O-alquilo C1-3, alquileno C1-3-(OH), NO2, -CN, -SO2NRaRb, -X-alquilo C1-3 o alquileno C1-3-X-alquilo C1- 3 en los que X representa S, SO o SO2, o bien Z representa un fenilo opcionalmente sustituido con un átomo de halogeno, un grupo alquilo C1-5, alcoxi C1-5 o fluoroalquilo C1-3, o bien Z representa un radical alquinilo del tipo -C:::C-Rc, en el que Rc representa un átomo de H, un grupo alquilo C1-3, alquileno C1-6-O-Rd o alquileno C1-6-NRaRb, o bien Z representa un grupo -alquileno C4-6-ORd, o bien Z representa un grupo tetrazol sustituido con un grupo alquilo C1-3, o bien Z representa un grupo -NRaRb, alquileno C1-6-NRaRb o -C(O)-NRaRb, -C(O)-alquilo C1-3, -C(O)-O-alquilo C1-4, -C(O)-cicloalquilo C3-6, o bien Z representa un radical oxo, o bien Z representa un grupo -O-alquileno C1-5-NRaRb, o bien dos radicales Z adyacentes forman juntos un grupo alquileno C1-3-dioxi; o bien Z representa un grupo -O-alquileno C0-3-heterociclo, opcionalmente sustituido con uno o varios grupos alquilo C1-3, oxo o -C(O)-alquilo C1-3, o bien Z representa un grupo -O-alquileno C1-5-O-Rd, o bien Z representa un grupo -O-alquileno C0-3-cicloalquilo C5-7 opcionalmente sustituido con un grupo -O-Rd, o bien Z representa un grupo -NRe-alquileno C0-3-heterociclo opcionalmente sustituido con uno o varios grupos alquilo C1-3, oxo o -C(O)-alquilo C1- 3, o bien Z representa un grupo -NRe-alquileno C2-5-O-Rd, o bien Z representa un grupo -O-alquileno C1-3-heteroarilo opcionalmente sustituido con uno o varios grupos alquilo C1-3, o bien Z representa un grupo -CONH-alquileno C1-5-NRaRb, o bien Z representa un grupo -CONH-alquileno C1-5-O-Rd, o bien Z representa un grupo -O-alquileno C1-3-C(O)-NRaRb, o bien Z representa un heterociclo diaminado bicíclico condensado o espiránico; Ra y Rb representan cada uno, de forma independiente el uno del otro, un átomo de H o un grupo alquilo C1-3 o -C(O)-alquilo C1-3, o bien Ra y Rb forman juntos, con el átomo de N al que están unidos, un heterociclo opcionalmente sustituido con uno o varios grupos alquilo C1-3, oxo, -NRaRb, hidroxi, alcoxi C1-3, alquileno C1-3-(OH) o -C(O)-alquilo C1-3; Rd representa un átomo de H o un grupo alquilo C1-3; Re representa un átomo de H o un grupo alquilo C1-3; en forma de base o de sal de adicion a un ácido, así como en forma de hidrato o de solvato, así como sus enantiomeros, diastereoisomeros y sus mezclas.Useful for metabolic disorders. Claim 1: Compound that responds to the general formula (1) in which: A represents a C1-4 alkylene group optionally substituted with one or more identical or different R9 groups from one another; B represents a C1-4 alkylene group optionally substituted with one or more identical or different R10 groups from one another; R9 and R10 each independently represent each other, an H atom or a C1-5 alkyl group; or R9 and R10 together form a single bond or a C1-4 alkylene group; L represents a single bond or a C1-2 alkylene group, -CH = CH- or -C ::: C-, the C1-2 alkylene groups and -CH = CH- being optionally substituted with one or more C1- alkyl substituents 2 or L represents a cycloprop-1,2-di-yl group; R represents an H atom or a C1-5 alkyl group, C1-3 fluoroalkyl, C3-6 cycloalkyl, -C (O) -C1-3 alkyl, C1-3 alkylene-C3-6 cycloalkyl, -CH2-C: :: CH, C2-4-NRaRb alkylene or C1-3-X-C1-3 alkylene in which X represents O or SO2; R1 represents an aryl or a heteroaryl; the aryl and heteroaryl groups being optionally substituted with one or several Z radicals identical or different from each other, R2 and R3 independently represent each other, an H atom or a C1-3 alkyl or C1-3 fluoroalkyl group ; or R2 and R3 together form, with the C atom that supports them, a cycloprop-1,1-di-yl group; R4 represents: an atom of H or a C1-5 alkyl group, C1-3 fluoroalkyl, C1-5 alkoxy, -SF5 or C1-3-alkylene-C1-3 alkyl in which X represents O or SO2, a group C1-5-NRaRb alkylene, an aryl or a heteroaryl; the aryl and heteroaryl groups being optionally substituted with one or several Z radicals identical or different from each other; R5 represents an H or halogen atom or a C1-5 alkyl group, C1-3 fluoroalkyl, C1-5 alkoxy, C3-6 cycloalkyl, C1-3 alkylene-C3-6 cycloalkyl, C1-3-O-alkyl alkylene C1-3, C1-3- alkylene (OH) or C1-3 alkylene-C1-3 alkyl in which X represents S, SO or SO2, or R5 represents a group -NRaRb, C1-3 alkylene-NRaRb , aryl, C1-3-aryl alkylene, -O-aryl, C1-3-O-aryl alkylene, C1-3-O-C1-3-aryl alkylene, heteroaryl or C1-3-heteroaryl alkylene; the aryl, C1-3-aryl alkylene, -O-aryl, C1-3-O-aryl alkylene, C1-3-O-C1-3-alkylene-aryl, heteroaryl and C1-3-heteroaryl optionally substituted groups being optionally with one or more identical or different Z radicals from each other, or R5 represents a heterocycle group, said heterocycle being optionally substituted with a C1-3 alkyl group, -C (O) -C1-3 alkyl, -C (O) -C1-3 fluoroalkyl, C1-3 alkylene-C3-6 cycloalkyl, C1-3-aryl alkylene or C1-3-heteroaryl alkylene; the C1-3-aryl alkylene and C1-3 alkylene heteroaryl groups being optionally substituted with one or more identical Z radicals different from each other; R7 represents an H or halogen atom or a C1-5 alkyl, C1-3 fluoroalkyl, C1-5 alkoxy, -COOH, -C (O) O-C1-3 alkyl, C1-3 fluoroalkoxy, C1- alkylene 3- (OH), -NO2, -CN or -X-C1-3alkyl in which X represents S, SO or SO2, or R7 represents a group -NRaRb, C1-3 alkylene-NRaRb, -C (O ) - NRaRb, -C (O) -C1-3alkyl, aryl, -O-aryl or heteroaryl; the aryl, -O-aryl and heteroaryl groups being optionally substituted with one or more identical or different Z radicals from each other; Z represents a halogen atom or a C1-5 alkyl group, C1-3 fluoroalkyl, C3-6 cycloalkyl, C1-3 alkylene-C3-6 cycloalkyl, a phenyl, C1-5 alkoxy, C1-3 fluoroalkoxy, C1- alkylene 3-O-C1-3 alkyl, C1-3 alkylene- (OH), NO2, -CN, -SO2NRaRb, -X-C1-3 alkyl or C1-3 alkylene-X-C1-3 alkyl in which X represents S, SO or SO2, or Z represents a phenyl optionally substituted with a halogen atom, a C1-5 alkyl, C1-5 alkoxy or C1-3 fluoroalkyl group, or Z represents an alkynyl radical of the type -C :: : C-Rc, in which Rc represents an atom of H, a C1-3 alkyl group, C1-6-O-Rd alkylene or C1-6-NRaRb alkylene, or Z represents a C4-6 alkylene group ORd, either Z represents a tetrazol group substituted with a C1-3 alkyl group, or Z represents a group -NRaRb, C1-6 alkylene-NRaRb or -C (O) -NRaRb, -C (O) -C1 alkyl -3, -C (O) -O-C1-4alkyl, -C (O) -C3-6cycloalkyl, or Z represents an oxo radical, or Z represents a C1-5-NRaRb -O-alkylene group or either two adjacent Z radicals together form a C1-3-dioxy alkylene group; Either Z represents a -0-C0-3 alkylene-heterocycle group, optionally substituted with one or more C1-3 alkyl, oxo or -C (O) -C1-3alkyl groups, or Z represents a -O- group C1-5-O-Rd alkylene, or Z represents a C0-3 -C-alkylene-C5-7 alkylene group optionally substituted with a -O-Rd group, or Z represents a C0-3 -N-alkylene group -heterocycle optionally substituted with one or several C1-3 alkyl, oxo or -C (O) -C1-3 alkyl groups, or Z represents a C2-5-O-Rd -NRe-alkylene group, or Z represents a -O-C1-3 alkylene-heteroaryl group optionally substituted with one or more C1-3 alkyl groups, or Z represents a -CONH-C1-5-NRaRb group, or Z represents a -CONH-C1-alkylene group 5-O-Rd, or Z represents a group -O-C1-3-C alkylene (O) -NRaRb, or Z represents a condensed or spicylic bicyclic diamine heterocycle; Ra and Rb each independently represent each other, an atom of H or a C1-3 alkyl group or -C (O) -C1-3 alkyl, or Ra and Rb form together, with the atom of N to which they are attached, a heterocycle optionally substituted with one or more C1-3 alkyl groups, oxo, -NRaRb, hydroxy, C1-3 alkoxy, C1-3 alkylene- (OH) or -C (O) -C1 alkyl 3; Rd represents an atom of H or a C1-3 alkyl group; Re represents an H atom or a C1-3 alkyl group; in the form of base or salt of addition to an acid, as well as in the form of hydrate or solvate, as well as its enantiomers, diastereoisomers and mixtures thereof.

ARP060104457A 2005-10-12 2006-10-11 DERIVATIVES OF THE 4- AMINO - QUINAZOLINA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AR056688A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510409A FR2891829A1 (en) 2005-10-12 2005-10-12 4-AMINO-QUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF

Publications (1)

Publication Number Publication Date
AR056688A1 true AR056688A1 (en) 2007-10-17

Family

ID=36645639

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104457A AR056688A1 (en) 2005-10-12 2006-10-11 DERIVATIVES OF THE 4- AMINO - QUINAZOLINA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS

Country Status (5)

Country Link
AR (1) AR056688A1 (en)
FR (1) FR2891829A1 (en)
TW (1) TW200732308A (en)
UY (1) UY29857A1 (en)
WO (1) WO2007042669A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009001043A (en) 2006-08-08 2009-02-06 Sanofi Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use.
BRPI0912988A2 (en) * 2008-05-22 2019-09-24 Allergan Inc bicyclic compounds having cxcr4 receptor activity.
AR072707A1 (en) 2008-07-09 2010-09-15 Sanofi Aventis HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2443016T3 (en) 2009-08-26 2014-02-17 Sanofi New crystalline hydrates of heteroaromatic fluoroglycosides, pharmaceutical products comprising these compounds, and their use
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP4219449A3 (en) 2016-03-16 2023-10-11 Kura Oncology, Inc. Substituted indole derivatives and methods of preparation thereof
CN109640987B (en) 2016-03-16 2022-12-02 库拉肿瘤学公司 Bridged bicyclic inhibitors of MENIN-MLL and methods of use
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126087A1 (en) * 1982-09-24 1984-11-28 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO2003028641A2 (en) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
EP1534703A2 (en) * 2002-06-12 2005-06-01 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
WO2004052370A2 (en) * 2002-12-11 2004-06-24 7Tm Pharma A/S Quinoline compounds for use in mch receptor related disorders
CL2004000409A1 (en) * 2003-03-03 2005-01-07 Vertex Pharma COMPOUNDS DERIVED FROM 2- (REPLACED CILO) -1- (AMINO OR REPLACED OXI) -CHINAZOLINE, INHIBITORS OF IONIC SODIUM AND CALCIUM VOLTAGE DEPENDENTS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF ACUTE PAIN, CHRONIC, NEU
JP2008526734A (en) * 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド Quinazoline derivatives effective in preventing diabetes and obesity

Also Published As

Publication number Publication date
WO2007042669A2 (en) 2007-04-19
TW200732308A (en) 2007-09-01
WO2007042669A3 (en) 2007-05-31
FR2891829A1 (en) 2007-04-13
UY29857A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
AR056688A1 (en) DERIVATIVES OF THE 4- AMINO - QUINAZOLINA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
AR057980A1 (en) DERIVATIVES OF THE 1- AMINO-FTALAZINA REPLACED, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION
AR056689A1 (en) DERIVATIVES OF 1- AMINO-ISOQUINOLINE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
AR119698A2 (en) AMIDE COMPOUND N-UREA SUBSTITUTED AMINO ACID DERIVED
AR072657A1 (en) RAF INHIBITING COMPOUNDS AND METHODS FOR USE
AR059184A1 (en) DERIVATIVES OF SULFONAMIDS, ITS PREPARATION AND THEIR APPLICATION IN TARAPEUTICA
AR088534A1 (en) PESTICIDED COMPOSITIONS AND PROCESSES RELATED TO SUCH COMPOSITIONS
CO6160296A2 (en) BENZOAZEPIN-OXI-ACETIC ACID DERIVATIVES AS RECEPTOR AGONISTS ACTIVATED BY DELTA PEROXISONE PROLIFERATOR USED TO INCREASE HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL-CHOLESTEROL REDUCE LIPOPROTEIN-LOW DENSITY-COLESTEROL
AR050540A1 (en) DERIVATIVES OF TRICICLIC ADAMANTILAMIDE AS INHIBITORS OF DEHYDROGENASE 11- BETA HYDROXYSTEROID
AR081626A1 (en) AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
AR063988A1 (en) HETEROCICLIC DERIVATIVES, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR053774A1 (en) DERIVATIVES OF SULFONILBENCIMIDAZOL. PHARMACEUTICAL COMPOSITIONS.
AR059516A1 (en) ISOXAZOLINE DERIVATIVES, OBTAINING PROCESSES AND HERBICIDE COMPOSITIONS
PE20141405A1 (en) NEW DERIVATIVES OF INDOLIZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR063723A1 (en) 5-OXO-5,8-DIHIDRO-PYRIDOPIRIMIDINAS INHIBITORAS OF C-FMS KINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS ANTICANCER AGENTS, IN CARDIOVASCULAR DISEASES AND INFLAMMATORY PROCESSES
AR076435A1 (en) COMPOUNDS OF REPLACED INDAZOLS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESSES TO OBTAIN THEMSELVES
AR052568A1 (en) DERIVATIVES OF PIRAZOLO-PYRIMIDINE AS ANGLOSTS OF MGLUR2
AR051995A1 (en) TIENO-PYRIDINE DERIVATIVES AS GABA -B ALLOSTERIC INTENSIFIERS
AR062677A1 (en) DERIVATIVES OF BIARIL-SULFONAMIDE, PRODUCTION PROCESSES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR066669A1 (en) IMIDAZOLONA DERIVATIVES AS INHIBITORS OF BENCIMIDAZOLONA QUIMASA. PHARMACEUTICAL COMPOSITIONS.
AR073136A1 (en) PIRROL COMPOUNDS
ECSP11010901A (en) USEFUL AMIDA COMPOUNDS IN THERAPY
AR078536A1 (en) PIRAZOL DERIVATIVES AS LEGANDS OF THE STROGEN RECEIVER
AR086198A1 (en) REPLACED INHIBITORS OF ACETIL-COA CARBOXYLASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR057929A1 (en) AMIDINFENYL COMPOUNDS AND ITS USE AS FUNGICIDES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal